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Abstract
Recent studies have shown that gene mutations are involved in the pathology of neurological disorders. CCG repeats cause genetic
instability and are localized at the 5Vend of the non-coding regions of the FMR1 gene in fragile X syndrome. Our studies for the first time
showed that aluminum (Al) levels were elevated in the serum samples of fragile X syndrome and also provide evidence for the interaction of
aluminum with (CCG)12-repeats. Circular dichroism spectroscopic studies of (CCG)12 indicated B-DNA conformation and in the presence of
Al (105 M) CCG repeats attained Z-DNA conformation. Further spectroscopic studies, which included melting profiles, ethidium bromide
binding patterns and interaction of Z-DNA specific polyclonal antibodies confirmed the Z-conformation in (CCG)12-repeats in the presence
of Al (105 M). It is interesting to mention that Al-induced Z-conformation is stable even after the total removal of Al from CCG by
desferoximine, a chelating drug. This is the first report to proof the role of Al in modulating the DNA (CCG repeats) topology and this
information provides a clue about the possible involvement of Al at a molecular level in neurological/neurodegenerative disorders.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
DNA molecule is polymorphic in nature having many
conformations [1–5] and these conformational changes are
regulated by specific DNA sequences. Right-handed B-DNA
conformation is the most predominant conformation in bio-
logical systems. Non-B-DNA conformations also occur in
vivo like Z-DNA, triple helix and tetraplexes [6–8]. DNA
topology has been proposed to have a crucial role in DNA
transcription and susceptibility of DNA for oxidative dam-
age [9]. The expansion of DNA-triplet repeats defines a new
type of mutation in the human genome, namely ‘‘dynamic
mutation’’ leading to genomic instability [10–14]. Mutation
studies have revealed that abnormal expansion of CCG,
CGG, CTG, CAG etc., were implicated in more than 12
neurological disorders [11]. GC*-rich triplet repeats CCG,
CGG, GCC, GGC are predominantly involved in fragile X
neurodisorder [11,15–19]. These repeats are localized both
in coding and non-coding regions of genes [11,15,16].
Further, the expansion of these repeats differ, depending on
the location of the repeat tract in the gene, and the con-
sequences range from reduction of transcription initiation to
protein toxicity [19].
Aluminum (Al) is one of the strong suspected etiological
factors in neurodegenerative disorders like Alzheimer’s,
Parkinsonism and GuamParkinsonism/amyotrophic lateral
sclerosis [20–23]. In the present study, we have reported for
the first time elevated concentrations of Al in the serum
samples of fragile X syndrome patients, thus providing a
clue on possible role of Al in fragile X neurodisorder.
Studies from our laboratory [24,25] and elsewhere [26]
show that Al preferentially binds to DNA. However, our
studies show for the first time that Al strongly binds to AT*-
rich sequences with no conformational transition [25],
where it causes a Z!A helical transition in GC*-rich
oligomers [24]. From this perspective, it is important to
know whether the topology of CCG repeats play a vital role
in fragile X neurodisorders through the modulation of tran-
0925-4439/02/$ - see front matter D 2002 Elsevier Science B.V. All rights reserved.
PII: S0925 -4439 (02 )00133 -3
* Corresponding author. Fax: +91-821-517233.
E-mail address: kjr4n@yahoo.com (K.S.J. Rao).
y Recently deceased.
www.bba-direct.com
Biochimica et Biophysica Acta 1588 (2002) 56–64
scription of FMR1 gene. We hypothesize that DNA top-
ology in these repeats plays an important role in the
expression of FMR1 gene. Keeping the above complexity
in view, the topology of (CCG)12-long repeats and the role
of Al in modulating CCG topology was studied. Further, the
relevance of these topological changes to the expression of
FMR1 gene was hypothesized.
2. Materials and methods
2.1. Aluminum levels in the serum of fragile X syndrome
patients
Blood samples from 10 fragile X syndrome patients and
10 normal (no etiology of any neurological disorders)
humans were collected from J.S.S. Medical College and
Hospital, Mysore, India and the serum samples were sepa-
rated. Al levels were estimated using Inductively coupled
Plasma Atomic Emission Spectrometer (ICPAES) model JY
38 at wavelength 396.152 nm with detection limit at 0.002
ppm. The optimization of ICPAES was evaluated by line
selection and detection limits and validation of analysis was
tested by analyzing certified standard reference material
(bovine liver 1577a) [27,28].
2.2. Ethical issue
Ethical approval for collecting blood samples from
fragile X syndrome and normal humans was obtained from
the Research Ethical Committee of J.S.S. Hospital. A
written consent was obtained from the patients/carers prior
to the collection of blood samples.
2.3. CCG repeats synthesis
The (CCG)12 repeats were synthesized by phosphorami-
dite technique using a 380B ABI automated DNA synthe-
sizer. Deprotection of the oligonucleotide bases were carried
out in the presence of ammonia at 55 jC for 12 h. The
samples were ethanol precipitated, FPLC purified and
freeze-dried.
2.4. Aluminum maltolate synthesis
Aluminum maltolate was prepared in our laboratory from
aluminum chloride hexahydrate and maltol (3-hydroxy-2-
methyl-4H-pyran-4-one) following the method of Finneagen
et al. [29].
2.5. Circular dichroism (CD) studies
CD spectra (210–330 nm) were recorded for (CCG)12
(5 10 4 M) in 0.01 M HEPES buffer (pH 7.5). The effect
of different concentrations of Al-maltolate (5 10 9 to
5 10 4 M) on the mean molar ellipticity values were
studied. CD spectra were also recorded to understand the
effect of the Al-chelating drug, desferoximine (5 10 5 M)
on Al–(CCG)12 (1:10 M) (the complex under Z-DNA
conformation) complex spectra. The CD spectra were
recorded on a JASCO-J500 Spectropolarimeter with 1 mm
width and 1 mm cell length. The spectra at each concen-
tration were averaged from four recordings. DNA conforma-
tions were characterized following the guidelines of Gray
et al. [30].
2.6. C–C* mismatch studies
C–C* mismatch base pair formation in CCG repeats in
the presence and absence of Al, was studied by monitoring
the increase in the magnitude of long-wavelength positive
CD band at 283 nm when pH was lowered from 7.0 to 5.0 in
the presence of 0.1 and 0.5 M Na +.
2.7. Melting temperature studies
The melting temperature curves for (CCG)12 (5.0
10 4 M) were determined in the presence or absence of
Al-maltolate (5.0 10 8 to 5.0 10 4 M) in 0.01 M
HEPES buffer (pH 7.5). Absorbance at 260 nm was recor-
ded at different temperatures (20–85 jC, 1 jC/min) using a
Gilford Response II UV spectrophotometer. Tm values were
determined graphically from the percent hyperchromicity
vs. temperature plots. The temperature studies were also
conducted in the presence and absence of Al-chelating drug
desferoximine (5 10 5 M). The precision in Tm values
estimated from the variance in three repeated experiments
was + 0.05 jC.
2.8. Fluorescence studies
Fluorescence emission studies were carried out using
equimolar concentrations of CCG repeats and ethidium
bromide (EtBr) (2.5 10 5:2.5 10  5 M (1:1)) solu-
tions. DNA/EtBr solutions were excited at 535 nm and
emission was monitored at 600 nm using JASCO J77
spectrofluorimeter. The effect of different concentrations
of Al (5 10 10 to 5 10 4 M) on the EtBr fluorescence
was investigated and the percentage decrease in EtBr
fluorescence was calculated. The effect of desferoximine
on the EtBr fluorescence of DNA/EtBr complex in the
presence of Al (5 10  10 to 5 10  4 M) was also
investigated.
2.9. ELISA
(CCG)12 (25 Ag/ml) were mixed with different concen-
trations of Al-maltolate (5 10 10 to 5 10 4 M) and
incubated for 30 min at room temperature. All solutions
were in HEPES buffer (pH 7.5). Titer plates were pre-coated
with 100 Al of protamine sulfate. After the incubation, the
CCG/Al mixture was diluted to a CCG concentration of 2.5
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Ag/ml with no EDTA in the buffer. One hundred microliters
of this mixture was added to micro titer plate and incubated
overnight at 4 jC. Anti-Z-polyclone was used in this ELISA
test. The absorbance was recorded at 410 nm.
2.10. Extra-helical alignment of CCG repeats
The possible alignment of CCG repeats were designed
with reference to anti-parallel staggered, anti-parallel, and
parallel and the bonding pattern with respect to Watson–
Crick base pair, mismatch and protonated were derived
theoretically using the Fresco and Alberts model [31]. The
possible alignments were represented in Fig. 6.
3. Results
3.1. Aluminum levels in the serum of fragile X syndrome
patients
Al levels were found to be 0.53 (F 0.06) 10 4 M and
1.8 (F 0.2) 10 4 M in normal and fragile X syndrome
affected persons, respectively. This data indicates that Al
level is high ( + 231%) in fragile X syndrome affected
persons.
3.2. Al-maltolate
Understanding the toxicity of Al is governed by the
speciation chemistry of Al over pH range. To overcome
this hydrolytic chemistry problem in the present study, a
highly soluble Al-maltolate is used. This Al complex is
hydrolytically stable from pH 2.0 to 12.0 and possesses a
neutral charge. It is highly soluble compound and enhances
free Al existence by 100-fold at neutral pH compared to any
other inorganic or organic Al complex and has been used as
a model compound to be used for understanding molecular
effects of Al in a biological system [32]. The application of
this compound in DNA conformational studies will over-
come Karlik et al.’s [26] complex explanation on Al
speciation–DNA interactions. Most of the researchers have
used inorganic salts of Al where the concentration of soluble
free Al at pH 7.0 will be 50 AM in a 10 mM solution. This
means free Al concentration is 10 12 M only and the rest of
Al is in Al(OH)3 precipitate form.
3.3. CD studies on DNA helicity
CD spectra of (CCG)12 indicated classical B-DNA con-
formation with a characteristic positive peak at 275 nm and a
negative peak at 245 nm (Fig. 1a). On addition of lower
concentrations (10 8 to 10 6M) of Al, there was a decrease
in the magnitude of both the positive and negative peaks at
275 and 245 nm, respectively (Fig. 1b). But at higher Al
concentrations (10  5 and 10 4 M), CCG attained Z-DNA
conformation with characteristic two negative peaks at 245
and 290 nm, and a positive peak at 260 nm (Fig. 1c and d).
The effect of Al-chelating drug, desferoximine (10  5M) on
Al–CCG complex (10  5 M of Al) indicated that the total
removal of Al by the drug could not reverse the spectral
characteristics back to B-conformation (free CCG) from Z-
conformation (CCG–Al complex) (Fig. 1e). The total
removal of Al from CCG complex was ensured by dialyzing
desferoximine/Al–CCG (10  5:10  5:10  5 M) complex
overnight in 0.001 M HEPES Buffer. The dialyzed CCG
was digested in nitric acid and Al content in the CCG was
estimated by ICPAES. We found no signal in the digested
CCG solution indicating total removal of Al from CCG-
oligomer by desferoximine.
3.4. ELISA
Z-DNA conformation was further confirmed using left-
handed Z-DNA-specific polyclonal antibody using ELISA
reader. The data confirmed the presence of left-handed Z-
DNA conformation in (CCG)12 at Al concentrations above
10 5 M (Fig. 2). Immunochemical assay of Z-DNA using
anti-Z–IgG polyclonal antibody at different Al concentra-
tions (A=Al (5 10 9 M), B =Al (5 10 7 M), C =Al
(5 10 6 M), D =Al (5 10 5 M) and E =Al (5 10 4
M)). Z-DNA conformationwas observed inD and E columns,
where Al concentration is 5 10 5 M and (5 10 4 M),
respectively.
Fig. 1. Effect of Al on CD spectra of (CCG)12 in 0.01 M HEPES buffer (pH
7.4): a=(CCG)12, b =Al (5 10 7 M), c =Al (5 10 5 M), d =Al
(5 10 4 M), e =Al (5 10 4 M) + desferoximine (5 10 4 M).
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3.5. C–C* mismatch studies
C–C* mismatch base pairing was detected by monitoring
CD changes at 283 nm with reference to pH 5.0 to 7.0 at 0.1
and 0.5 M Na + concentration. There was an increase in the
magnitude of long-wavelength positive band at 283 nmwhen
pH was lowered from 7.0 to 5.0 at 0.1 and 0.5 M Na,
indicating the formation of C–C* mismatch base pairs. The
lower concentration of Al (10  7 M) did not alter C–C*
mismatch base pair formation (Fig. 3). But higher concen-
tration of Al (10  4M) caused a reduction in C–C*mismatch
base pair formation, thus possibly favoring the stability of Z-
DNA conformation.
3.6. Melting temperature studies
The Tm value for (CCG)12 alone was found to be 48 jC.
The lower concentrations of Al (10  8 10 6M) decreased
the Tm to 42 jC. But higher concentrations of Al (10  4 M)
increased the Tm to 52 jC. However, the addition of the drug
desferoximine (10 4 M) on Al (10  4 M)/CCG complex did
not alter Tm (52 jC) indicating the stable conformation of
CCG complex even after Al is removed. However, desferox-
imine (10 4 M) could chelate Al (10  8 10 6 M) from
the CCG–Al complex and could reverse Tm from 42 to 48 jC
(Fig. 4).
Fig. 3. Effect of Al on CD spectra of (CCG)12 at 283 nm at different pH and Na
+ concentrations.o=(CCG)12 (10
 5 M),.=(CCG)12 (10 5 M) +Al (10 7 M),
E=(CCG)12 (10
 5 M) +Al (10 4 M).
Fig. 2. Immunochemical assay of Z-DNA using anti-Z– IgG polyclonal
antibody at different Al concentrations. A=Al (5 10 9 M), B =Al
(5 10 7 M), C =Al (5 10 6 M), D =Al (5 10 5 M), E =Al
(5 10 4 M).
Fig. 4. Effect of Al on Tm (jC) values of (CCG)12 oligomers in 0.01 M
HEPES buffer (pH 7.4). CCG=(CCG)12 oligomers alone, A=Al (5 10 8
M), B =Al (5 10 7 M), C =Al (5 10 6 M), D =Al (5 10 4 M),
E =Al (5 10 7 M) + desferoximine (5 10 4 M), F =Al (5 10 4
M) + desferoximine (5 10 4 M).
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3.7. Fluorescence studies
Fluorescence emission spectra were monitored for equi-
molar concentrations of DNA/EtBr in the presence and
absence of Al. On additions of different concentrations of
Al to CCG/EtBr solutions, the fluorescence emission
decreased in a concentration-dependent manner (Fig. 5).
The concentrations of Al that caused 75%, 50%, and 25%
reductions in EtBr fluorescence were 10 4, 10 6, and
10 7 M, respectively. The chelation of Al (10  4 M) by
the chelating drug, desferoximine (10  4 M) did not alter
the Al-induced EtBr fluorescence reduction (75%). This
data clearly confirmed, once again, the formation of Z-
DNA conformation in CCG repeats.
3.8. Extra-helical alignment of CCG repeats
Extra-helical alignment in CCG repeats showed the
alignment with reference to anti-parallel staggered, anti-
parallel, and parallel was designed. These alignments were
similar to what was predicted for polynucleotides by Fresco
and Alberts [31]. In the anti-parallel staggered conformation
5V-end, C– is unbound and free in nature in both the strands
and the number of mismatches were 11 in (CCG)12. The
number of mismatches in anti-parallel, and parallel align-
ments were 12. The above alignments of (CCG)12 triplet
repeats were represented in Fig. 6.
4. Discussion
Our studies for the first time evidence that Al brought
about helical transition from B- to Z-DNA conformation in
(CCG)12-repeats. The total removal of Al by chelating
drugs, namely desferoximine, did not reverse the Z-DNA
conformation to B-DNA, indicating the irreversible and
stable conformation. The molar concentration of Al in the
serum of fragile X syndrome is 1.8 10  4M. In the
Fig. 5. The effect of Al on percent change in EtBr fluorescence of (CCG)12
oligomers in 0.01 M HEPES buffer (pH 7.4). A=Al (5 10 8 M), B =Al
(5 10  7 M), C = Al (5 10  6 M), D = Al (5 10  4 M), E = Al
(5 10 4 M) + desferoximine (5 10 4 M).
Fig. 6. The possible alignments of (CCG)12 triplet repeats.
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present investigation, it was observed that 10 4 M and
10 5 M of Al could favor Z-conformation in CCG repeats.
It is interesting to mention that Al concentration recorded
(10  4 M) in serum could induce Z-DNA conformation in
(CCG)12 repeats and thus these findings have physiological
significance. Further, Al-induced Z-DNA conformation is
stable as evidenced by irreversibility of the conformation
even after total removal of Al by desferoximine. Z-DNA
conformation in CCG repeats could act physically to pre-
vent the movement or the binding of RNA polymerase, thus
modulating transcription. Therefore, in fragile X syndrome,
the FMR1 gene might have been turned off due to the
formation of Z-DNA by Al. We developed a hypothesis,
which is explained in a later part of this discussion in strong
support of the above concept. Thus, formation of Z-DNA
topology in CCG long repeats may have a biological
significance in molecular understanding of the role of
FMR1 gene in fragile X syndrome and the relevance of
Al in this neurological disorder.
The long CCG triplet repeats at the FRAXA site are
involved in the pathology of fragile X syndrome [11]. The
poor chromatin staining and the large expansions of the
CCG repeats block at the FRAXA site suggested an altered
chromatin structure and strong nucleosome exclusion [33].
It is hypothesized that Z-DNA conformation is also one of
the likely factors which favor exclusion of nucleosome
formation [34] and this will possibly explain the poor
chromatin staining of the fragile site. The nucleosome
formation depends on the bending and twisting elastic
energy to transform the DNA intrinsic super structure into
the nucleosome structure [35]. Z-DNA, being more rigid,
cannot bend to favor the formation of nucleosome. Thus,
DNA topology is very important for the histones protein
binding, and this binding favors the formation of nucleo-
somes and also RNA polymerase binding during transcrip-
tion [36,37]. It was previously shown that the Z-DNA
conformation depends largely on the sequence and on the
degree of negative super coiling [38].
4.1. Our hypothesis on how FMR1 gene regulation is
modulated by Al-mediated CCG* topology
4.1.1. Al-mediated DNA topological changes from B- to Z-
DNA
We hypothesize that the molecular involvement of Al in
bringing about B- to Z-DNA conformation may be due to
binding of Al to phosphate group and nitrogenous bases
which may affect sugar puckering in dG leading to C2V to
Fig. 7. Theoretical Model representing the melting temperature and EtBr binding pattern in CCG repeats (GC* region) under Al-induced DNA conformation
change.
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C3V endo pucker and the configuration of glycosidic bond
(torsion angle). Hence, negative super helical tension caused
by Al binding may drive local transitions (B-DNA) to
alternative DNA structures. This conformational change
may affect the expression of FMR1 gene. The C–C*
mismatches induce local flexibility to form non-B-DNA
conformation. During B- to Z-DNA helical transitions, the
intrastrand hydrogen bond distance between C–C* mis-
matches in B-DNA conformation should decrease due to Al
binding (N4–N3, 4.38 A˚ B-DNA; O2–O2, 3.54 A˚ Z-DNA)
in addition to change of torsion angle and sugar puckering
in dG. This may be the reason for the reduction in C–C*
mismatches at higher Al concentration leading to stable Z-
DNA conformation. This may be the reason why total
removal of Al by desferoximine could not reverse Z- to
B-DNA.
4.1.2. Z-DNA conformation stability pattern
The duplex (CCG)12 repeats with C–C* mismatch has
Tm of 48 jC. Al (10  7 M) has decreased Tm to 42 jC.
But at higher concentrations of Al (10  4 M), CCG has
higher Tm of 52 jC. The reduced Tm by lower concen-
trations of Al may be due to the formation of intermediary
and transition conformation from B-DNA. However, higher
concentrations of Al increased the Tm due to stable con-
formation. The reason might be transition of nitrogen bases
by 180 with respect to its B-conformation and change of
deoxyribose molecule from perpendicular to parallel with
respect to its helical axis. During this process, the hydrogen
bonds may break due to favorable transition energy towards
Z-conformation. Thus, the intermediary duplex needs less
energy to melt (a hypothetical model: Fig. 7). Once the Z-
conformation is attained, in addition to the usual three
hydrogen bonds between guanine and cytosine, a hydrogen
bond between N3 cytosine of one chain to NH2-C4-
cytosine and other bond between 02 and N3 (H) + is
observed. This is mainly because of Z-DNA conformation
by bringing two cytosine molecules (which are in anti-
conformation) nearer as compared to B-conformation and
this explains the higher energy to melt in the Z-DNA
duplex.
4.1.3. How Al could modulate FMR gene expression (Fig. 8)
Eukaryotic transcriptional control operates at three lev-
els: (a) modulation of the levels and/or activities of activa-
tors and repressors, (b) change in chromatin structure
Fig. 8. Hypothesis model representing the switching off and on of FMR1 gene in fragile X syndrome as function of DNA structural dynamics.
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directed by activators and repressors and (c) direct influence
of activators and repressors on assembly of initiation com-
plexes. Here, we hypothesize that Al-induced DNA top-
ology is relevant to FMR1 gene regulation (Fig. 8). The
promoter-proximal region at the 5V-end of FMR1 gene
contains GC*-rich sequences and also CGG triplet repeats.
This gene is hypothesized to be turned off when CCG/CGG
repeats are longer than 200 with methylation [39–44]. In
normal conditions, DNA is in B-conformation. The CCG
repressor protein or p20 binds in the major groove of
cognate site on B-DNA in a sequence-specific manner. This
interferes with the general transcription factors (GTF’s),
which play a role in the formation of transcription–initiation
complex and regulates gene repression. The binding and
removal of the p20 from its cognate site is likely to control
FMR1 gene expression. In conclusion, we provide for the
first time, evidence that Al induces B- to Z-DNA confor-
mation in CCG-rich repeats. In genetic neurodisorders, the
trinucleotide repeats will be more than 200 with hyper-
methylation at FMR1 operon and this might be in Z-DNA
conformation in the presence of Al. Under such conditions,
both p20 and GTF’s may not be able to assemble to form
transcription–initiation complex at its cognate site, because
there are no major grooves in Z-DNAW.
In our model, we concentrate on direct influence of Al on
activators and repressors on assembly of transcription–
initiation complex formation to explain the expression of
FMR1 gene. Similar to other eukaryotic genes, these genes
do have DNA regions coding for structural gene along with
upstream promoter–proximal region where transcriptional
factors (upstream transcriptional factors or UTF’s) bind in a
sequence-specific manner and stimulate/inhibit the forma-
tion of transcription–initiation complex formation (general
transcription factors or GTF’s). The FMR1 gene is known to
contain GC*-rich sequence in the promoter–proximal
region (5V-end), specific for UTF’s [39–44]. The suppres-
sion/over-expression of FMR1 gene plays an important role
in disease onset. Based on the gene expression during
normal and disease condition, we have postulated that
FMR1 gene is under repression control, since its expression
is affected by 5V-(CCG)n-3Vbinding protein [40,41].
Hence, these studies suggest that Al is likely to play a
role in switching off the FMR1 gene by inducing helical
transition from B- to Z-DNA, in addition to the factors
involved in massive expansion of CCG triplet repeats and
hypermethylation, imbalance in trace metal homeostasis,
etc. (Fig. 9). This mechanism may provide a clue for the
discovery of new drugs to convert Z-DNA back to B-DNA.
It is hypothesized that through chelation of metal ions like
aluminum, demethylation of the triplet repeats and acetyla-
tion of histones, it may be possible to switch on FMR 1
gene.
Fig. 9. The complexity of DNA topology in fragile X disorder.
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